Impact of baseline characteristics on the efficacy of once‐weekly subcutaneous semaglutide among participants with type 2 diabetes : A post hoc analysis of SUSTAIN China
Authors' conclusion
These results support the effectiveness of once-weekly subcutaneous semaglutide 0.5 and 1.0 mg across a broad range of baseline characteristics, in participants with T2D from SUSTAIN China.
Study context
- Population
- Participants with T2D from the SUSTAIN China trial; total and Chinese-only populations605 Chinese-only · Chinese-only 605
- Participants
- 868 participants
- Comparison
- Once-weekly SC semaglutide 0.5 and 1.0 mg vs sitagliptin 100 mg
- Primary endpoint
- Change in HbA1c and body weight by baseline age, sex, BMI, HbA1c, diabetes duration and HOMA-β tertile
- Follow-up
- Baseline to end of treatment
Methodological detailssubgroup analysis by baseline characteristics
- Subgroup analysis by baseline characteristics
Primary result
As reported in the abstract
Efficacy (HbA1c, body weight) by baseline characteristics · end of treatment
- Proportion achieving HbA1c <7% not affected by baseline HbA1c
- pinteraction > 0.05
Further findings
| Outcome | P value |
|---|---|
| HOMA-β ratio to baseline · end of treatmentSemaglutide 0.5 mg vs Sitagliptin 100 mg · greater with semaglutide | P < 0.05 |
| HOMA-β ratio to baseline · end of treatmentSemaglutide 1.0 mg vs Sitagliptin 100 mg · greater with semaglutide | P < 0.05 |
Glucose variability (self-monitored plasma glucose (SMPG) fluctuation, derived time-in-range (dTIR) of seven-point SMPG) · Week 30
- Less glucose variability with semaglutide 0.5 and 1.0 mg vs sitagliptin
Original publication
Impact of baseline characteristics on the efficacy of once‐weekly subcutaneous semaglutide among participants with type 2 diabetes : A post hoc analysis of SUSTAIN China. Diabetes Obes Metab. Published 16 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →